Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 2

PubMed

B-cell maturation antigen-targeted chimeric antigen receptor T cell therapy (BCMA CAR-T) is an effective treatment for relapsed refractory multiple myeloma (RRMM). However the pattern of infectious complications is not well-elucidated. We performed a single-center retrospective analysis of infection …

  • As we use more CART in myeloma, we acquire familiarity with the unique side effect profile of these modalities. This important retrospective work by Kambhampati et al of 55 patients with myeloma receiving CART demonstrates several important facts. Firstly, Grade III/IV neutropenia is almost universal (98%) in the month following transplant. Infections overall happened in 53% of patients in the 6 months post CART, although reassuringly most were mild. The most common site of infection was the respiratory tract. Owing to the small sample size, definitive risk factors for infection could not be established in this study, and should be an area for future research. Nevertheless, I take solace in the rarity of severe infections post CART from this study, and eagerly look forward to additional data as we get acquainted with this therapy.